
Tardoc under pressure: what invoice criticism reveals
Individual cases raise important questions – but they do not yet prove systemic fraud
The criticism is pointed: a system that tempts people to cheat is not a good system. The trigger is an investigation by the French-speaking Swiss programme «À bon entendeur», reported on by Medinside. Among other things, it describes the case of a patient who received two eye injections at separate appointments, although this had previously been done in a single consultation. The clinic justified the split with medical considerations such as infection risk and monitoring for possible side effects. According to the report, the patient's general practitioner did not share this assessment. A Council of States member from Neuchâtel described certain practices as illegal, while a specialist physician conversely criticised cuts in remuneration and wrong incentives.
The case is relevant because it touches on a central question of any tariff reform: does the way providers are paid change the course of treatment? Even so, it would be wrong to infer fraud or a nationwide practice from a single example. Whether an additional appointment is medically justified and correctly billed can only be judged on the basis of the specific case, the documentation and the tariff rules in force. The investigation provides grounds for scrutiny – not robust evidence of widespread misconduct.
What has changed since January
Since 1 January 2026, the outpatient sector has not simply been governed by «the Tardoc», but by an overall tariff system made up of two parts. Tardoc is a fee-for-service tariff: medical services as well as infrastructure and staff services are assigned tax points, which are converted into francs using canton-specific point values. Alongside it stand outpatient flat rates. They remunerate certain standardisable treatments with a fixed amount or a fixed number of tax points.
This combination is deliberate. With it, the Federal Council wanted to replace the TARMED structure, which is more than twenty years old, and correct wrong incentives. The Federal Office of Public Health itself notes that flat rates can reduce the incentive for inflated invoices that fee-for-service tariffs can create. But that does not mean every fee-for-service invoice is suspect. It remains necessary for many outpatient treatments, especially when services are less standardised or do not fall under a flat rate.
Where the critical interface lies
The difficult questions arise precisely at this interface. If certain services may not be billed together, or not in the same way, economic pressure can emerge to change workflows. Whether this actually happens in a given case must not be presumed but must be examined. Medical reasons can justify separate appointments. Conversely, splitting appointments solely to increase remuneration would be problematic. Careful auditing must distinguish between the two possibilities.
Cost neutrality, too, is often misunderstood. Under the rules, the switch from TARMED to the new system must not lead to higher costs simply because the tariff structure is new. That is a requirement for the transition at system level. It cannot be inferred from this that every patient receives the same invoice as before, or that every individual service develops in the same way. New valuations can remunerate some services more and others less. What matters is whether the system change is cost-neutral overall and whether the services provided remain economical and medically appropriate.
Scrutinising early warning signs consistently
The reform is still young. The Federal Council approved the overall system for a limited period until the end of 2028, so that necessary adjustments remain possible after introduction. To that end, the tariff partners founded the Organisation ambulante Arzttarife; from 2027 the structures are to be updated for the first time and then further developed annually. That is no excuse for mistakes, but it is important context: wrong incentives appearing early should be examined quickly with data and, where necessary, corrected in the tariff rules.
What would make sense now? First, transparent and comparable analyses are needed on whether the number of appointments, billing volumes and treatment pathways change noticeably for certain procedures. Second, insurers and the responsible authorities must consistently examine individual conspicuous invoices instead of deriving blanket accusations from suspected cases. Third, patients need understandable communication. Anyone who receives additional appointments can ask about the medical justification and have an invoice explained by the practice or the insurer.
The investigation therefore performs an important function: it makes visible where a new tariff system could create undesirable incentives. Its strongest finding is not that Tardoc has already failed. It is that the tariff partners, supervisory authorities and insurers must now show whether they can recognise such signals, investigate them properly and correct them quickly.
Sources
- Medinside: «Tardoc: a system that tempts people to cheat», 14 October 2026
- FOPH: Tardoc and outpatient flat rates – the new tariff system
- FOPH: Outpatient medical tariff – system, cost neutrality and approval
- FOPH: Fact sheet on the new medical tariff, 29 September 2026
- FOPH: Approval of the overall tariff system by the Federal Council, 30 April 2025


